Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, both of which address significant unmet medical needs. With a focus on expanding its pipeline and global reach, Acadia is advancing multiple clinical trials, including therapies for Prader-Willi syndrome and Alzheimer's disease psychosis.
This description was generated via AI from an annual report. Updated about 1 year ago.